![logo](/logos/RAPT.webp)
RAPT Therapeutics, Inc.
NASDAQ:RAPT
1.83 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | RAPT Therapeutics, Inc. |
Symbool | RAPT |
Munteenheid | USD |
Prijs | 1.83 |
Beurswaarde | 63,873,405 |
Dividendpercentage | 0% |
52-weken bereik | 1.81 - 27.35 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Brian Russell Wong M.D., Ph.D. |
Website | https://www.rapt.com |
An error occurred while fetching data.
Over RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)